2-(Tert-butoxy)propan-1-amine | 339306-19-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(Tert-butoxy)propan-1-amine
• 英文别名: 2-[(2-methylpropan-2-yl)oxy]propan-1-amine
• CAS: 339306-19-3
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: FUMQINKTMJGGNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(Tert-butoxy)propan-1-amine 、 2-(溴甲基)苯甲酰氯 、 溴乙酸 、 Fmoc-S-(4-甲氧基三苯甲基)-L-半胱氨酸 生成 (5R)-12-(2-hydroxypropyl)-7,10,13-trioxo-3-thia-6,9,12-triazabicyclo[12.4.0]octadeca-1(18),14,16-triene-5-carboxamide
  参考文献：
  名称：

  Cyclic Semipeptoids:  Peptoid−Organic Hybrid Macrocycles

  摘要：

  Cyclic semipeptoids 1 and 2 represent constrained, secondary structure mimics where the R-1 and R-2 side chains correspond to those of amino acids. Solid-phase syntheses and conformational analyses of these compounds are described.

  DOI：

  10.1021/ol052867d

文献信息

• Protein-Polymer-Drug Conjugates
  申请人：Yurkovetskiy Aleksandr

  公开号：US20120321583A1

  公开（公告）日：2012-12-20

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种药物结合物。该结合物包括一种基于蛋白质的识别分子（PBRM）和一个聚合物载体，该载体被一个或多个-LD-D取代，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是分子量≦5 kDa的治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接剂。还公开了用于与PBRM结合形成聚合物-药物-PBRM结合物的聚合物支架，包括结合物的组成，其制备方法以及使用结合物或其组成物治疗各种疾病的方法。
• Auristatin Compounds and Conjugates Thereof
  申请人：Mersana Therapeutics, Inc.

  公开号：US20130309192A1

  公开（公告）日：2013-11-21

  Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently an Auristatin compound. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了Auristatin化合物及其共轭物。该共轭物包括基于蛋白质识别分子（PBRM）的识别分子和被取代一个或多个-LD-D的聚合物载体，其中蛋白质识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的Auristatin化合物。LD和LP是连接治疗剂和PBRM到聚合物载体的连接剂。本文还揭示了用于与PBRM共轭形成聚合物-药物-PBRM共轭物的聚合物支架，包括所述共轭物的组成，其制备方法以及使用共轭物或其组成治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150044160A1

  公开（公告）日：2015-02-12

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供一种药物偶联物。该偶联物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，其取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的，其分子量≦5 kDa，是一种治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接体。还公开了用于与PBRM偶联形成聚合物-药物-PBRM偶联物的聚合物支架，包括所述偶联物的组合物，其制备方法以及使用偶联物或其组合物治疗各种疾病的方法。
• Terminally Modified Polymers and Conjugates Thereof
  申请人：Mersana Therapeutics, Inc.

  公开号：US20140017265A1

  公开（公告）日：2014-01-16

  A terminally modified polymer is provided herein. At least one terminus of the polymer is —O—(CH 2 ) 2 -L M or —O—CH 2 —CH(OH)—CH 2 —CR 1 ═CR 2 R 3 . L M , R 1 , R 2 , and R 3 are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种终止修饰的聚合物。聚合物的至少一个端点是—O—（CH2）2-LM或—O— —CH（OH）— —CR1═CR2R3。其中LM，R1，R2和R3在本文中有定义。此外，本文还披露了包括该聚合物和药物有用修饰剂的终端共轭物，以及包括共轭物的组合物、其制备方法以及使用共轭物或其组合物治疗各种疾病的方法。
• HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150306240A1

  公开（公告）日：2015-10-29

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric scaffold having one or more -L D -D, the PBRM being connected to the polymeric scaffold by L p , wherein the polymeric scaffold comprises a linear, branched or cyclic polymer having four or more —OH groups. Each occurrence of D is independently a therapeutic agent having a molecular weight <5 kDa. L D and L p are linkers connecting the therapeutic agent and PBRM to the polymeric scaffold respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种药物结合物。该结合物包括一种基于蛋白质的识别分子（PBRM）和一个具有一个或多个-LD-D的聚合物支架，其中PBRM通过Lp连接到聚合物支架上，聚合物支架包括具有四个或更多—OH基团的线性、分支或环状聚合物。每个D的出现都是独立的，具有分子量<5 kDa的治疗剂。LD和Lp是连接治疗剂和PBRM到聚合物支架的连接剂。还公开了用于与PBRM结合形成聚合物-药物-PBRM结合物的聚合物支架，包括结合物的组成，其制备方法以及使用结合物或其组成物治疗各种疾病的方法。